Neisvac-C

Tetanus toxoid, algeldrate, Neisseria meningitidis group C polysaccharide, the active ingredient in Neisvac-C, is a vaccine presented as an injectable solution for intramuscular use. It provides active immunity against tetanus and meningococcal group C disease in individuals at risk.

Originating from the European Union, GNH USA supplies Neisvac-C as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Neisvac-C is used to stimulate protective immunity against tetanus toxin and the capsular polysaccharide of Neisseria meningitidis group C. - Tetanus: Provides active protection against tetanus in individuals without adequate immunity. - Meningococcal group C disease: Induces antibodies that help prevent invasive disease caused by Neisseria meningitidis group C. - Post‑exposure prophylaxis for tetanus: Used as part of the recommended regimen to prevent tetanus after potential wound contamination.

Neisvac-C may be associated with local and systemic reactions following intramuscular administration.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the site of injection. - Redness and swelling: localized erythema and edema. - Fever: transient low‑grade temperature rise. - Headache: mild headache occurring within 24 hours. - Fatigue: temporary feeling of tiredness. - Myalgia: muscle aches around the injection area.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder with ascending weakness. - Seizures: infrequent occurrence, especially in individuals with pre‑existing conditions. - Hypotension: sudden drop in blood pressure post‑vaccination.

Before administering Neisvac-C, healthcare professionals should consider the following precautions. - Allergy assessment: Verify no known hypersensitivity to tetanus toxoid, algeldrate, or meningococcal polysaccharide. - Acute illness: Defer vaccination in persons with moderate or severe febrile illness until recovery. - Immunocompromised patients: Use with caution, as response may be reduced. - Concomitant vaccines: Observe recommended intervals when given with other live vaccines. - Pregnancy and lactation: Evaluate risk‑benefit; limited data available. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Neisvac-C can interact with other agents, influencing immune response or safety.

Major Interactions (Avoid): - Live attenuated vaccines: Avoid simultaneous administration to prevent interference with immune response. - Immunoglobulin therapy: Do not give within 2 weeks before or after vaccination as it may diminish antibody production.

Moderate Interactions (Monitor Closely): - Other inactivated vaccines: May be co‑administered but monitor for increased reactogenicity. - Antipyretics: Prophylactic acetaminophen may reduce antibody response; consider timing. - Immunosuppressive drugs: May lower vaccine efficacy; assess need for revaccination.